THERAVANCE BIOPHARMA INC (TBPH) Stock Fundamental Analysis
USA - NASDAQ:TBPH - KYG8807B1068 - Common Stock
17.885 USD
+0.16 (+0.87%)
We assign a fundamental rating of 4 out of 10 to TBPH. TBPH was compared to 192 industry peers in the Pharmaceuticals industry. TBPH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, TBPH is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
TBPH had negative earnings in the past year.
TBPH had a positive operating cash flow in the past year.
TBPH had negative earnings in 4 of the past 5 years.
TBPH had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
TBPH's Return On Assets of 7.06% is amongst the best of the industry. TBPH outperforms 88.54% of its industry peers.
TBPH's Return On Equity of 12.61% is amongst the best of the industry. TBPH outperforms 88.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.06% | ||
| ROE | 12.61% | ||
| ROIC | N/A |
ROA(3y)37.73%
ROA(5y)0.15%
ROE(3y)46.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 36.53%, TBPH belongs to the best of the industry, outperforming 97.40% of the companies in the same industry.
TBPH does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 36.53% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TBPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TBPH has been increased compared to 1 year ago.
Compared to 5 years ago, TBPH has less shares outstanding
The debt/assets ratio for TBPH is higher compared to a year ago.
2.2 Solvency
TBPH has an Altman-Z score of 0.68. This is a bad value and indicates that TBPH is not financially healthy and even has some risk of bankruptcy.
TBPH's Altman-Z score of 0.68 is in line compared to the rest of the industry. TBPH outperforms 55.21% of its industry peers.
The Debt to FCF ratio of TBPH is 0.13, which is an excellent value as it means it would take TBPH, only 0.13 years of fcf income to pay off all of its debts.
TBPH has a Debt to FCF ratio of 0.13. This is amongst the best in the industry. TBPH outperforms 96.35% of its industry peers.
A Debt/Equity ratio of 0.14 indicates that TBPH is not too dependend on debt financing.
TBPH's Debt to Equity ratio of 0.14 is in line compared to the rest of the industry. TBPH outperforms 47.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.14 | ||
| Debt/FCF | 0.13 | ||
| Altman-Z | 0.68 |
ROIC/WACCN/A
WACC8.78%
2.3 Liquidity
A Current Ratio of 9.48 indicates that TBPH has no problem at all paying its short term obligations.
The Current ratio of TBPH (9.48) is better than 79.17% of its industry peers.
TBPH has a Quick Ratio of 9.48. This indicates that TBPH is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 9.48, TBPH is in the better half of the industry, outperforming 79.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.48 | ||
| Quick Ratio | 9.48 |
3. Growth
3.1 Past
The earnings per share for TBPH have decreased strongly by -10.53% in the last year.
TBPH shows a strong growth in Revenue. In the last year, the Revenue has grown by 27.12%.
TBPH shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.59% yearly.
EPS 1Y (TTM)-10.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%126.92%
Revenue 1Y (TTM)27.12%
Revenue growth 3Y5.2%
Revenue growth 5Y-2.59%
Sales Q2Q%18.51%
3.2 Future
Based on estimates for the next years, TBPH will show a very strong growth in Earnings Per Share. The EPS will grow by 27.85% on average per year.
The Revenue is expected to grow by 30.15% on average over the next years. This is a very strong growth
EPS Next Y186.4%
EPS Next 2Y32.82%
EPS Next 3Y36.41%
EPS Next 5Y27.85%
Revenue Next Year80.96%
Revenue Next 2Y28.84%
Revenue Next 3Y19.99%
Revenue Next 5Y30.15%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TBPH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TBPH. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
97.40% of the companies in the same industry are more expensive than TBPH, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.7 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
TBPH's earnings are expected to grow with 36.41% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.82%
EPS Next 3Y36.41%
5. Dividend
5.1 Amount
TBPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:TBPH (11/20/2025, 2:30:45 PM)
17.885
+0.16 (+0.87%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners92.18%
Inst Owner Change5.12%
Ins Owners4.57%
Ins Owner Change-3.09%
Market Cap900.69M
Revenue(TTM)80.33M
Net Income(TTM)29.34M
Analysts80
Price Target21.25 (18.81%)
Short Float %10.57%
Short Ratio13.03
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-12.59%
Min EPS beat(2)-178.66%
Max EPS beat(2)153.48%
EPS beat(4)1
Avg EPS beat(4)-21.5%
Min EPS beat(4)-178.66%
Max EPS beat(4)153.48%
EPS beat(8)2
Avg EPS beat(8)-16.75%
EPS beat(12)4
Avg EPS beat(12)-14.07%
EPS beat(16)4
Avg EPS beat(16)-30.83%
Revenue beat(2)0
Avg Revenue beat(2)-1.58%
Min Revenue beat(2)-1.81%
Max Revenue beat(2)-1.36%
Revenue beat(4)1
Avg Revenue beat(4)0.44%
Min Revenue beat(4)-2.67%
Max Revenue beat(4)7.58%
Revenue beat(8)3
Avg Revenue beat(8)-0.1%
Revenue beat(12)4
Avg Revenue beat(12)-3.78%
Revenue beat(16)6
Avg Revenue beat(16)-3.51%
PT rev (1m)0%
PT rev (3m)16.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)63.75%
EPS NY rev (1m)0%
EPS NY rev (3m)141.08%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)47.77%
Revenue NY rev (1m)0%
Revenue NY rev (3m)18.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 11.21 | ||
| P/FCF | 3.7 | ||
| P/OCF | 3.7 | ||
| P/B | 3.87 | ||
| P/tB | 3.87 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.05
EYN/A
EPS(NY)-0.26
Fwd EYN/A
FCF(TTM)4.83
FCFY27.03%
OCF(TTM)4.84
OCFY27.06%
SpS1.6
BVpS4.62
TBVpS4.62
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.06% | ||
| ROE | 12.61% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 36.53% | ||
| GM | N/A | ||
| FCFM | 303.11% |
ROA(3y)37.73%
ROA(5y)0.15%
ROE(3y)46.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score9
Asset Turnover0.19
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.14 | ||
| Debt/FCF | 0.13 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | -13.08% | ||
| Cap/Sales | 0.28% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 829.74% | ||
| Current Ratio | 9.48 | ||
| Quick Ratio | 9.48 | ||
| Altman-Z | 0.68 |
F-Score9
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)53.03%
Cap/Depr(5y)62.83%
Cap/Sales(3y)1.99%
Cap/Sales(5y)4.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%126.92%
EPS Next Y186.4%
EPS Next 2Y32.82%
EPS Next 3Y36.41%
EPS Next 5Y27.85%
Revenue 1Y (TTM)27.12%
Revenue growth 3Y5.2%
Revenue growth 5Y-2.59%
Sales Q2Q%18.51%
Revenue Next Year80.96%
Revenue Next 2Y28.84%
Revenue Next 3Y19.99%
Revenue Next 5Y30.15%
EBIT growth 1Y16.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y259.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y262.26%
OCF growth 3YN/A
OCF growth 5YN/A
THERAVANCE BIOPHARMA INC / TBPH FAQ
What is the fundamental rating for TBPH stock?
ChartMill assigns a fundamental rating of 4 / 10 to TBPH.
Can you provide the valuation status for THERAVANCE BIOPHARMA INC?
ChartMill assigns a valuation rating of 2 / 10 to THERAVANCE BIOPHARMA INC (TBPH). This can be considered as Overvalued.
How profitable is THERAVANCE BIOPHARMA INC (TBPH) stock?
THERAVANCE BIOPHARMA INC (TBPH) has a profitability rating of 3 / 10.
How financially healthy is THERAVANCE BIOPHARMA INC?
The financial health rating of THERAVANCE BIOPHARMA INC (TBPH) is 6 / 10.
What is the expected EPS growth for THERAVANCE BIOPHARMA INC (TBPH) stock?
The Earnings per Share (EPS) of THERAVANCE BIOPHARMA INC (TBPH) is expected to grow by 186.4% in the next year.